Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focusing on gene and cell therapies, announced that its CEO, Helen Sabzevari, PhD, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 PM PT in San Francisco, California. Participants can register to view the event on Precigen's website under the Events & Presentations section. Precigen is advancing therapies in immuno-oncology and other critical areas, working towards innovative solutions in biotherapeutics.

GERMANTOWN, Md., Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PT/6:45 PM ET in San Francisco, California.

Participants may register and view this event through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations. 

###

Precigen: Advancing Medicine with Precision™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com

Media Contacts:
Donelle M. Gregory
press@precigen.com 

Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301706404.html

SOURCE Precigen, Inc.

FAQ

What is Precigen presenting at the J.P. Morgan Healthcare Conference on January 11, 2023?

Precigen will present a corporate and clinical overview led by CEO Helen Sabzevari, PhD.

What time is Precigen's presentation at the J.P. Morgan Healthcare Conference?

Precigen's presentation is scheduled for January 11, 2023, at 3:45 PM PT.

Where can I register to view Precigen's presentation?

You can register to view Precigen's presentation on their website in the Events & Presentations section.

What is the focus of Precigen's therapies?

Precigen focuses on developing gene and cell therapies, particularly in immuno-oncology, autoimmune disorders, and infectious diseases.

What stock symbol represents Precigen?

Precigen is represented by the stock symbol PGEN.